{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:14Z","timestamp":1787239934254,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["# 2023_EKEA.16"],"award-info":[{"award-number":["# 2023_EKEA.16"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) is characterized by chemotherapy resistance, partly driven by its dense and heterogeneous tumor microenvironment (TME). Since most preclinical PDAC models inadequately capture the tissue architecture, their translational value for therapeutic testing remains limited. This study investigated organotypic tissue slice cultures (OTSCs), which preserve the multicellular tissue architecture, as a rapid platform for personalized ex vivo drug response profiling. OTSCs were generated from 27 resected PDAC specimens. Following workflow establishment and quality control, ex vivo drug profiling was performed in 15 patients using gemcitabine, gemcitabine plus paclitaxel, and FOLFIRINOX. Treatment response was assessed by quantitative digital pathology, and an ex vivo sensitivity score (EVSS) was defined. Clinical correlations with longitudinal follow-up were assessed in ten patients. OTSCs preserved tissue architecture and revealed interpatient heterogeneity. In exploratory analyses of clinically matched patients, ex vivo sensitivity was associated with prolonged PFS (median 445 vs. 141 days, log-rank\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0027; HR per 10 EVSS points 0.625; 95% CI 0.484\u20130.807,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.00032), while lower preoperative CA 19-9 levels and higher GATA6 expression were associated with higher EVSS and longer overall survival. OTSC-based profiling enables rapid, patient-specific drug response assessment in PDAC and supports evaluation as a functional stratification tool.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01663-z","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:45:54Z","timestamp":1787237154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Benjamin","family":"Heckelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fetzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lapshyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashinikumar Singh","family":"Hidam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maxi","family":"Wandmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"F\u00e4rber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannis","family":"Duhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"ten Winkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Bolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Honselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Deichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Carstven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Keber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Gemoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Sebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Wellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"1663_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913\u20132921 (2014).","journal-title":"Cancer Res."},{"key":"1663_CR2","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1663_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","volume":"17","author":"C Nevala-Plagemann","year":"2020","unstructured":"Nevala-Plagemann, C., Hidalgo, M. & Garrido-Laguna, I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat. Rev. Clin. Oncol. 17, 108\u2013123 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1663_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 19, 439\u2013457 (2021).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"1663_CR5","doi-asserted-by":"publisher","first-page":"e812","DOI":"10.1055\/a-1856-7346","volume":"60","author":"T Seufferlein","year":"2022","unstructured":"Seufferlein, T. et al. S3-Leitlinie zum exokrinen Pankreaskarzinom \u2013 Langversion 2.0 \u2013 Dezember 2021 \u2013 AWMF-Registernummer: 032\/010OL. Z. Gastroenterol. 60, e812\u2013e909 (2022).","journal-title":"Z. Gastroenterol."},{"key":"1663_CR6","doi-asserted-by":"publisher","unstructured":"Bailey, P. et al. Refining the treatment of pancreatic cancer from big data to improved individual survival. Function 4, https:\/\/doi.org\/10.1093\/function\/zqad011 (2023).","DOI":"10.1093\/function\/zqad011"},{"key":"1663_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).","journal-title":"Nat. Commun."},{"key":"1663_CR8","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","volume":"23","author":"MA Lowery","year":"2017","unstructured":"Lowery, M. A. et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin. Cancer Res. 23, 6094\u20136100 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1663_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian, M. J. et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 21, 508\u2013518 (2020).","journal-title":"Lancet Oncol."},{"key":"1663_CR10","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.3390\/ijms21197307","volume":"21","author":"M Huber","year":"2020","unstructured":"Huber, M. et al. The immune microenvironment in pancreatic cancer. Int. J. Mol. Sci. 21, 7307 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1663_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1663_CR12","unstructured":"Springfeld, C. & B\u00fcchler, M. W. An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature. https:\/\/www.aio-portal.de\/studie\/116--espac-6.html (2024)."},{"key":"1663_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.tranon.2017.04.009","volume":"10","author":"L Bolm","year":"2017","unstructured":"Bolm, L. et al. The role of fibroblasts in pancreatic cancer: extracellular matrix versus paracrine factors. Transl. Oncol. 10, 578\u2013588 (2017).","journal-title":"Transl. Oncol."},{"key":"1663_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","volume":"178","author":"M Ligorio","year":"2019","unstructured":"Ligorio, M. et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178, 160\u2013175.e127 (2019).","journal-title":"Cell"},{"key":"1663_CR15","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","volume":"184","author":"BT Gr\u00fcnwald","year":"2021","unstructured":"Gr\u00fcnwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577\u20135592.e5518 (2021).","journal-title":"Cell"},{"key":"1663_CR16","doi-asserted-by":"crossref","unstructured":"Group Young Researchers In Inflammatory Carcinogenesis. Wandmacher, A. M., Mehdorn, A. S. & Sebens, S. The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer. Cancers 13, 4932 (2021).","DOI":"10.3390\/cancers13194932"},{"key":"1663_CR17","doi-asserted-by":"publisher","first-page":"e1333210","DOI":"10.1080\/2162402X.2017.1333210","volume":"6","author":"X Jiang","year":"2017","unstructured":"Jiang, X. et al. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Oncoimmunology 6, e1333210 (2017).","journal-title":"Oncoimmunology"},{"key":"1663_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.pan.2018.09.009","volume":"18","author":"CY Lim","year":"2018","unstructured":"Lim, C. Y. et al. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response. Pancreatology 18, 913\u2013927 (2018).","journal-title":"Pancreatology"},{"key":"1663_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38603-w","volume":"9","author":"S Misra","year":"2019","unstructured":"Misra, S. et al. Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. Sci. Rep. 9, 2133 (2019).","journal-title":"Sci. Rep."},{"key":"1663_CR20","doi-asserted-by":"publisher","unstructured":"Braun, R. et al. Organotypic slice cultures as preclinical models of tumor microenvironment in primary pancreatic cancer and metastasis. J. Vis. Exp. https:\/\/doi.org\/10.3791\/62541 (2021).","DOI":"10.3791\/62541"},{"key":"1663_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jprot.2018.01.012","volume":"188","author":"E Sereti","year":"2018","unstructured":"Sereti, E. et al. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer? J. Proteom. 188, 107\u2013118 (2018).","journal-title":"J. Proteom."},{"key":"1663_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3390\/cancers12051327","volume":"12","author":"PL Garcia","year":"2020","unstructured":"Garcia, P. L., Miller, A. L. & Yoon, K. J. Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models. Cancers 12, 1327 (2020).","journal-title":"Cancers"},{"key":"1663_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"1663_CR24","doi-asserted-by":"publisher","first-page":"965182","DOI":"10.3389\/fonc.2022.965182","volume":"12","author":"CF Moro","year":"2022","unstructured":"Moro, C. F. et al. Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma. Front. Oncol. 12, 965182 (2022).","journal-title":"Front. Oncol."},{"key":"1663_CR25","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston, D. R. & Davis, M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin. Cancer Res. 23, 3489\u20133498 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1663_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81299-0","volume":"11","author":"J Kokkinos","year":"2021","unstructured":"Kokkinos, J. et al. Ex vivo culture of intact human patient derived pancreatic tumour tissue. Sci. Rep. 11, 1944 (2021).","journal-title":"Sci. Rep."},{"key":"1663_CR27","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"1663_CR28","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane, G. M. et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 26, 4901\u20134910 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1663_CR29","doi-asserted-by":"publisher","unstructured":"Heckelmann, B., Duhn, J. & Braun, R. Current advances in preclinical patient-derived cultivation models for individualized drug response prediction in pancreatic cancer. Oncol. Res. https:\/\/doi.org\/10.32604\/or.2026.075028 (2026).","DOI":"10.32604\/or.2026.075028"},{"key":"1663_CR30","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1158\/1078-0432.CCR-19-1984","volume":"26","author":"R Braun","year":"2020","unstructured":"Braun, R. et al. Single-cell\u2013derived primary rectal carcinoma cell lines reflect intratumor heterogeneity associated with treatment response. Clin. Cancer Res. 26, 3468\u20133480 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1663_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.670","volume":"12","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma. Clin. Transl. Med. 12, e670 (2022).","journal-title":"Clin. Transl. Med."},{"key":"1663_CR32","doi-asserted-by":"publisher","unstructured":"F\u00e4rber, B. et al. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Front. Oncol. 13, https:\/\/doi.org\/10.3389\/fonc.2023.1230382 (2023).","DOI":"10.3389\/fonc.2023.1230382"},{"key":"1663_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65911-3","volume":"10","author":"M Ghaderi","year":"2020","unstructured":"Ghaderi, M. et al. Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. Sci. Rep. 10, 9070 (2020).","journal-title":"Sci. Rep."},{"key":"1663_CR34","doi-asserted-by":"publisher","unstructured":"Szekerczes, T. et al. Exploration of patient-derived pancreatic ductal adenocarcinoma ex vivo tissue for treatment response. Antioxidants 12, https:\/\/doi.org\/10.3390\/antiox12010167 (2023).","DOI":"10.3390\/antiox12010167"},{"key":"1663_CR35","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","volume":"25","author":"YD Seo","year":"2019","unstructured":"Seo, Y. D. et al. Mobilization of CD8(+) T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer. Clin. Cancer Res. 25, 3934\u20133945 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1663_CR36","doi-asserted-by":"publisher","unstructured":"Rohila, D. et al. Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-3645 (2023).","DOI":"10.1158\/0008-5472.CAN-22-3645"},{"key":"1663_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/SLA.0000000000004200","volume":"272","author":"TT Sepp\u00e4l\u00e4","year":"2020","unstructured":"Sepp\u00e4l\u00e4, T. T. et al. Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer. Ann. Surg. 272, 427\u2013435 (2020).","journal-title":"Ann. Surg."},{"key":"1663_CR38","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3390\/cancers13112539","volume":"13","author":"AK Beutel","year":"2021","unstructured":"Beutel, A. K. et al. A prospective feasibility trial to challenge patient\u2013derived pancreatic cancer organoids in predicting treatment response. Cancers 13, 2539 (2021).","journal-title":"Cancers"},{"key":"1663_CR39","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-11-0341","volume":"17","author":"I Garrido-Laguna","year":"2011","unstructured":"Garrido-Laguna, I. et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17, 5793\u20135800 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1663_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-10-125","volume":"10","author":"DJ Monsma","year":"2012","unstructured":"Monsma, D. J. et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J. Transl. Med. 10, 1\u201318 (2012).","journal-title":"J. Transl. Med."},{"key":"1663_CR41","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8, 1112\u20131129 (2018).","journal-title":"Cancer Discov."},{"key":"1663_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jso.25976","volume":"122","author":"AC Gamboa","year":"2020","unstructured":"Gamboa, A. C. et al. Optimal timing and treatment strategy for pancreatic cancer. J. Surg. Oncol. 122, 457\u2013468 (2020).","journal-title":"J. Surg. Oncol."},{"key":"1663_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/labinvest.2017.131","volume":"98","author":"P Bankhead","year":"2018","unstructured":"Bankhead, P. et al. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. Lab. Investig. 98, 15\u201326 (2018).","journal-title":"Lab. Investig."},{"key":"1663_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94544-3","volume":"11","author":"K Duan","year":"2021","unstructured":"Duan, K. et al. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Sci. Rep. 11, 14951 (2021).","journal-title":"Sci. Rep."},{"key":"1663_CR45","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO.2005.05.3934","volume":"24","author":"CR Ferrone","year":"2006","unstructured":"Ferrone, C. R. et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 24, 2897\u20132902 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1663_CR46","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdr561","volume":"23","author":"JL Humphris","year":"2012","unstructured":"Humphris, J. L. et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann. Oncol. 23, 1713\u20131722 (2012).","journal-title":"Ann. Oncol."},{"key":"1663_CR47","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1245\/s10434-018-6521-7","volume":"25","author":"CJ Rieser","year":"2018","unstructured":"Rieser, C. J. et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann. Surg. Oncol. 25, 3483\u20133491 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"1663_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"1663_CR49","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0003","volume":"3","author":"TG Meijer","year":"2017","unstructured":"Meijer, T. G., Naipal, K. A., Jager, A. & van Gent, D. C. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Sci. OA 3, FSO190 (2017).","journal-title":"Future Sci. OA"},{"key":"1663_CR50","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.3390\/cancers13194991","volume":"13","author":"JR Weitz","year":"2021","unstructured":"Weitz, J. R., Tiriac, H., Hurtado de Mendoza, T., Wascher, A. & Lowy, A. M. Using organotypic tissue slices to investigate the microenvironment of pancreatic cancer: pharmacotyping and beyond. Cancers 13, 4991 (2021).","journal-title":"Cancers"},{"key":"1663_CR51","doi-asserted-by":"publisher","unstructured":"Sauerbrei, W., Haeussler, T., Balmford, J. & Huebner, M. Structured reporting to improve transparency of analyses in prognostic marker studies. BMC Med. 20, https:\/\/doi.org\/10.1186\/s12916-022-02304-5 (2022).","DOI":"10.1186\/s12916-022-02304-5"},{"key":"1663_CR52","unstructured":"GraphPad Software, I. Graphpad QuickCalcs: Quantify agreement with kappa, https:\/\/www.graphpad.com\/quickcalcs\/kappa2\/ (2024)."},{"key":"1663_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41374-018-0123-7","volume":"99","author":"B Acs","year":"2019","unstructured":"Acs, B. et al. Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. Lab. Investig. 99, 107\u2013117 (2019).","journal-title":"Lab. Investig."},{"key":"1663_CR54","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.jpi.2023.100198","volume":"14","author":"HJG Smits","year":"2023","unstructured":"Smits, H. J. G. et al. Validation of automated positive cell and region detection of immunohistochemically stained laryngeal tumor tissue using digital image analysis. J. Pathol. Inf. 14, 100198 (2023).","journal-title":"J. Pathol. Inf."},{"key":"1663_CR55","doi-asserted-by":"publisher","first-page":"e0245638","DOI":"10.1371\/journal.pone.0245638","volume":"16","author":"S Ram","year":"2021","unstructured":"Ram, S. et al. Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images. PLOS ONE 16, e0245638 (2021).","journal-title":"PLOS ONE"},{"key":"1663_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1663_CR57","doi-asserted-by":"publisher","unstructured":"Cong, L. et al. Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic cancer patients after radical resection and adjuvant chemotherapy. Sci. Rep. 8 https:\/\/doi.org\/10.1038\/s41598-018-28193-4 (2018).","DOI":"10.1038\/s41598-018-28193-4"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01663-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:06:13Z","timestamp":1787238373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01663-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01663-z","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests. A patent application related to this work has been filed by the authors\u2019 institution and is currently pending. The patent applicant is Universit\u00e4t zu L\u00fcbeck. The named inventors are Benjamin Heckelmann and R\u00fcdiger Braun. The application number is 25202687.7-1111. The patent application covers OTSC-based ex vivo drug response profiling and treatment sensitivity assessment. Specific manuscript-related aspects covered by the application include OTSC drug profiling, quantitative ex vivo response assessment, derivation of the EVSS, and correlation of ex vivo treatment sensitivity with clinical outcome. The value of this patent application may be affected by publication of the manuscript. The authors declare no other competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"325"}}